XML 57 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Segment Information
3 Months Ended
Jan. 31, 2020
Segment Reporting [Abstract]  
Business Segment Information Business Segment Information
The Company discloses information about its operating segments, which were established based on the way that management organizes segments within the Company for making operating decisions and assessing financial performance. The Company's two operating segments are described below.
CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. CooperVision designs its products to solve vision challenges such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues, with a broad collection of spherical, toric and multifocal contact lenses.
CooperSurgical. Competes in the general health care market with a focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women's health, fertility, diagnostics and contraception.
Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results.
Total identifiable assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets.
Segment information:
Three Months Ended January 31,
 
(In millions)
2020
 
2019
CooperVision net sales by category:
 
 
 
Toric lens
$
155.1

 
$
146.0

Multifocal lens
51.8

 
49.1

Single-use sphere lens
138.1

 
132.1

Non single-use sphere, other
140.2

 
142.9

Total CooperVision net sales
$
485.2

 
$
470.1

CooperSurgical net sales by category:
 
 
 
Office and surgical products
98.5

 
95.7

Fertility
62.5

 
62.3

CooperSurgical net sales
161.0

 
158.0

Total net sales
$
646.2

 
$
628.1

Operating income:
 
 
 
CooperVision
$
122.9

 
$
116.3

CooperSurgical
1.7

 
7.2

Corporate
(13.5
)
 
(12.6
)
Total operating income
111.1

 
110.9

Interest expense
11.6

 
18.2

Other expense (income), net
2.1

 
(1.1
)
Income before income taxes
$
97.4

 
$
93.8


(In millions)
January 31, 2020
 
October 31, 2019
Total identifiable assets:
 
 
 
CooperVision
$
4,163.2

 
$
3,911.6

CooperSurgical
2,226.6

 
2,189.8

Corporate
158.7

 
173.1

Total
$
6,548.5

 
$
6,274.5


Geographic information:
Three Months Ended January 31,
 
(In millions)
2020
 
2019
Net sales to unaffiliated customers by country of domicile:
 
 
 
United States
$
293.5

 
$
278.9

Europe
213.4

 
209.7

Rest of world
139.3

 
139.5

Total
$
646.2

 
$
628.1



(In millions)
January 31, 2020
 
October 31, 2019
Net property, plant and equipment by country of domicile:
 
 
 
United States
$
649.6

 
$
626.5

Europe
361.9

 
358.8

Rest of world
157.0

 
146.8

Total
$
1,168.5

 
$
1,132.1